MedWatch

Orphazyme: Anticipated product approval to secure transformational year

Orphazyme predicts lower operating result in transformational 2021.

Photo: Orphazyme/PR

Danish biotechnology firm Orphazyme, which develops medication for rare diseases, forecasts an operating deficit at DKK 100m-150m (USD 16.2m-24.2m) in 2021, which is significantly lower than the realized deficit for 2020 at DKK 608m, according to the firm's 2020 annual report.

"We expect 2021 to be a transformational year for Orphazyme with the anticipated approval and launch of arimoclomol in NPC (Niemann-Pick type C, -ed.) and two key readouts from our late-stage clinical trials in IBM (inclusion body myositis, -ed.) and ALS (amyotrophic lateral sclerosis, -ed.)," the firm writes in the report.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs